Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP, Human Resources | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,025 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,025 · Balance 8,025 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2019 Filed Aug 5, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 80 | $243.06 | $19,444.80 |
DisclosureSEC source: 0001127602-19-026026 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,215 Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 179 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026026 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 128 | $243.06 | $31,111.68 |
DisclosureSEC source: 0001127602-19-026026 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,116 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,890 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · derivative · entry 8 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,890 Underlying: Common Stock · 6,890 shares Expires 2022-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 814 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · derivative · entry 7 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,788 Underlying: Common Stock · 814 shares Expires 2021-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,078 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · derivative · entry 6 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,602 Underlying: Common Stock · 1,078 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 758 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · derivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,517 Underlying: Common Stock · 758 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 317 | $319.43 | $101,259.31 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 234 | $319.43 | $74,746.62 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:10 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 758 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006080 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:14 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 164 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024587 · form4.xml · derivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 854 Underlying: Common Stock · 164 shares Expires 2020-08-01 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F2 · derivative.underlying_shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 262 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024587 · form4.xml · derivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018 Underlying: Common Stock · 262 shares Expires 2020-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 85 | $344.06 | $29,245.10 |
DisclosureSEC source: 0001127602-18-024587 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 959 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 78 | $344.06 | $26,836.68 |
DisclosureSEC source: 0001127602-18-024587 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-024587 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:40 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006184 · form4.xml · derivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,680 Underlying: Common Stock · 5,680 shares Expires 2021-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:40 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,275 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006184 · form4.xml · derivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,275 Underlying: Common Stock · 2,275 shares Expires 2020-02-12 F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:34 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 1,280 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024875 · form4.xml · derivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 Underlying: Common Stock · 1,280 shares Expires 2020-08-01 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:34 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 860 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024875 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 860 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.